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rates: 1.15 and 1.51 for 1A and 1B respectively, p < 0.01).
Mean (SD) costs of care at one year of follow-up also
were reduced among GA patients ($9,522 [$9,706] vs.
$9,957 [$9,083] and $10,185 [$9,526] for 1A and 1B
respectively). Findings persisted in multivariate analyses
controlling for differences in demographic characteristics
and propensity scores for immunomodulatory therapy.
CONCLUSIONS: Glatiramer acetate is associated with
reductions in the incidence of relapse and costs of care
relative to the beta interferons among this large group of
managed-care patients with MS.
NEUROLOGICAL DIESEASES/DISORDERS &
PAIN—Quality of Life
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USE OF THE TOPS AS A PAIN-SPECIFIC 
HRQOL INSTRUMENT
Oderda GM, Lipman AG,Ashburn MA, Stockdale W
University of Utah, Salt Lake City, UT, USA
The Total Outcome of Pain Scale, TOPS, is a fully vali-
dated disease-speciﬁc outcome measurement tool for use
in patients with chronic pain. The TOPS provides much
greater sensitivity and speciﬁcity for measuring outcomes.
The 60°V-item TOPS questionnaire contains the SF-36
and information on Pain Symptom, Functional 
Limitations, Perceived Family/Social Disability, Real
Family/Social Disability and Formal Work Disability.
Unlike the SF-36, TOPS is precise enough to monitor
outcome over time in individual patients. All patients at
the University of Utah Pain Management Center complete
TOPS at evaluation, three months, six months, and then
every six months for the duration of therapy. Paper forms
are scanned into an Access database. This produces a
report that summarizes current and prior TOPS scores for
the patient and which is put into the patient’s medical
record. From July 1, 1997 through August 2, 2001, 3454
TOPS instruments were completed and entered. This rep-
resented 2692 individual patients. Most (80.5%) of
patients completed one TOPS; the remainder had 2 or
more. This population was 62.2% female and had the fol-
lowing characteristics (median values): age (40–44), years
of education (13), income $30,000–$39,999. The 6 most
common diagnoses and ICD 9 codes were: myalgia and
myositis, unspeciﬁed (729.11, low back pain, low back
syndrome (724.2), pain in limb (729.5), neuralgia, neuri-
tis, and radiculitis, unspeciﬁed (729.2), cervicalgia, pain
in neck (723.1) and headache (784.0). Mean responses
were as follows: ICD 9 Code PCS MCS Pain Symptom
Score Work Disability 729.1 28.9 39.7 72.2 37.7 724.2
27.1 40.1 72.9 47.4 729.5 27.9 40.4 75.3 38.7 729.2
28.9 40.1 73.0 46.8 723.1 30.5 37.6 73.2 40.1 784.0
31.6 37.6 71.2 31.8. Data collection is ongoing, with
20–30 surveys completed weekly. By the end of 2002,
data on approximately 5000 TOPS administrations will
be available and will be included in the presentation.
Querying the database may provide valuable data on rel-
ative outcomes by intervention and clinician.
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PHYSICIAN PREFERENCE FOR ANTIEPILEPTIC
DRUG CONCENTRATION TESTING
Baumann RJ, Ryan M,Yellowitz AS
University of Kentucky, Lexington, KY, USA
OBJECTIVES: To determine rate of adoption of saliva
concentrations as a monitoring method for antiepileptic
drugs (AEDs). To determine whether child neurologists
would prefer saliva testing to serum testing to obtain 
AED concentrations for clinical practice. METHODS:
A survey asked participants about use, availability, and
value to the physician of saliva AED concentrations.
Respondents chose between the following four responses
when considering value: 1) Very valuable, willing to
spend 1/2 hour of time per patient to arrange; 2) Moder-
ately valuable, willing to spend 10 minutes of time per
patient to arrange; 3) Not very valuable, might use test
but would not spend extra time to arrange; and 4) Of no
special value, I doubt that I would use such a test. All
members of the Child Neurology Society were surveyed.
Surveys were re-mailed to non-responders after one- and
two-month intervals. RESULTS: We mailed 1006 surveys
and received 546 responses (54%) and 57 surveys were
returned undelivered. Less than 1% of respondents had
obtained a saliva AED concentration in the last year.
Seven percent stated there was an available laboratory to
perform saliva AED concentration determinations. Fifty-
three percent of individuals indicated that having a pain-
free method of AED concentration determination was
very or moderately valuable to them and 68% stated that
the ability to obtain real-time samples outside of the clin-
ical environment was very or moderately valuable. CON-
CLUSIONS: Most child neurologists have not obtained
saliva AED concentrations and perceive they do not have
this technology available to them. The majority of respon-
dents would be willing to spend 10–30 minutes of time
to arrange for saliva AED concentrations to prevent
patient discomfort and obtain real-time concentrations.
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QUALITY OF LIFE (QOL) AND
PHARMACOECONOMICAL ASPECTS IN
PATIENTS WITH SYMPTOMATIC
LOCALIZATION-RELATED EPILEPSIES (SLE) 
IN MOSCOW
Guekht AB1, Gusev EI1, Belousov JB1, Bykov AV2,
Dzugaeva FK1, Milchakova LE1, Mitrokhina TV1
1Russian State Medical University, Moscow, Russia; 2Russian
Society for Pharmacoeconomics Research, Moscow, Russia
OBJECTIVES: The growing attention to the social aspect
of epilepsy and the necessity to improve the system of 
care require knowledge of QOL and pharmacoeconomic
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aspects. The purpose of the study was to evaluate the
QOL in 223 patients (age 18–70 years old) with SLE and
to estimate the cost-effectiveness of the optimization of
treatment (OT). METHODS: After appropriate investi-
gation, patients received the optimized treatment with
adequate carbamazepine or valproate monotherapy. (Pre-
viously 139 patients were on inadequate treatment with
low-dose polytherapy, 84 patients were untreated). 
Frequency, severity (NHS3 scale, M.F. Donoghue et al.,
1996) of seizures and QOL (QOLIE-31 scale, J. Cramer
1998) were analyzed as effectiveness parameters before
and 1 year after the OT. RESULTS: After OT complete
control of seizures (CCS) was achieved in 122 patients
(54.7%). Before OT the signiﬁcant (p < 0,01) negative
correlation was found between the QOLIE-31 overall
score (OS) and the duration of disease (r = -0,34), sever-
ity (r = -0,33) and frequency of seizure. In patients with
CCS the improvement of QOL was the most signiﬁcant.
QOL in patients with remaining rare seizures was signiﬁ-
cantly lower than in CCS group. Clinical efﬁcacy/tolera-
bility, QOL improvement, cost-effectiveness parameters
were similar on carbamazepine or valproate, that sup-
ports the use of valproate as adequate ﬁrst-line drugs in
patients with SLE. In patients with initial inadequate
polytherapy the cost of 100% remission (CCS) after OT
(valproate monotherapy) was 125 USD per year. CON-
CLUSIONS: Duration of epilepsy, severity, frequency of
seizures have the main impact on QOL. Complete control
of seizures is essential for improvement of QOL. Results
of pharmacoeconomical analysis support the necessity of
OT in epilepsy patients.
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EVALUATION OF THE RELATIONSHIP
BETWEEN EPILEPSY SEVERITY AND UTILITY
Selai C1, Kaiser S2,Trimble M1, Price M3
1UCL Institute of Neurology, London, Middlesex, United
Kingdom; 2University of Heidelberg, Heidelberg, Germany;
3Janssen-Cilag, High Wycombe, Bucks, United Kingdom
OBJECTIVES: Epilepsy has a signiﬁcant impact on the
patient, with higher frequency of seizures being associ-
ated with lower quality of life. The association between
utility and epilepsy clinical status is less well deﬁned. In
this analysis, we present utility values that were collected
during a prospective study of patients with intract-
able epilepsy and describe the association between utility
scores and clinical status. METHODS: One hundred
twenty-ﬁve patients with intractable epilepsy were
recruited at a tertiary referral centre in London, UK. At
recruitment, each patient was about to start treatment
with a new adjunctive anti-epileptic drug (AEDs). Pa-
tients were interviewed at baseline, three months and 
six months. At each visit patients completed a semi-
structured interview, the National Hospital seizure 
severity and frequency scale and the EuroQol EQ-5D.
Results are presented for both the EQ-5D tariff and VAS
(visual analogue) scores. Clinical response was deter-
mined as a 50% or greater reduction in baseline median
seizure frequency. RESULTS: At baseline, mean EQ utility
score was 0.850, (VAS = 65.08). Mean values were lower
in patients with higher seizure frequency, with utility
scores of 0.798, 0.902 and 0.934 in patients with >10,
2–9 and £1 seizure per month, respectively. VAS scores
were 62.85, 66.96 and 70.71 for these groups. At 6
months, 20/125 patients had become seizure-free, with a
mean utility value of 0.923 (VAS = 77.63), compared with
0.824 (VAS = 66.56) in patients who did not achieve a
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